MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling

Piotr Jasinski; Pawel Zwolak; Kaoru Terai; Rachel Isaksson Vogel; Daniel Borja-Cacho; Arkadiusz Z. Dudek

MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling

Piotr Jasinski, Pawel Zwolak, Kaoru Terai, Rachel Isaksson Vogel, Daniel Borja-Cacho, Arkadiusz Z. Dudek

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The novel compound thiopyrano [2,3-c]quinoline (MT477) has been shown to exhibit antitumor activity in both in vitro and in vivo studies. The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. Materials and Methods/Results: Molecular function analysis revealed changes in genes involved in cell death, cell-cycle progression and cellular growth and proliferation in all three cancer cell lines. Canonical pathway analysis showed the involvement of the NRF2-mediated oxidative stress response, glucocorticoid, p53, RXR-VDR, G₁/S checkpoint regulation, ERK, SAPK/JNK and JAS/Stat signaling. Analysis of 234 kinases and phosphatases using a kinase inhibition assay demonstrated a strong inhibitory effect for MAPK14 (104±2%), AMPK A2/B1/G1 (89%) and FGR (83±2%). AURKA was inhibited at 77±1%. MiaPaCa-2 tumor xenograft studies showed a 49.5±14.8% inhibitory effect in mice treated with 100 μg/kg MT477 compared to untreated mice (p=0.0021). Conclusion: MT477 induces molecular mechanisms related to cell death, survival, and inhibition of cellular growth in vitro and in vivo.

Original language	English (US)
Pages (from-to)	1181-1187
Number of pages	7
Journal	Anticancer Research
Volume	31
Issue number	4
State	Published - Apr 1 2011

Keywords

AURKA
MT477
NRF2
Tumor growth

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

OpenUrl availability

Full text

Cite this

@article{70e74ca8303642bc94e96fc44e047509,

title = "MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling",

abstract = "Background: The novel compound thiopyrano [2,3-c]quinoline (MT477) has been shown to exhibit antitumor activity in both in vitro and in vivo studies. The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. Materials and Methods/Results: Molecular function analysis revealed changes in genes involved in cell death, cell-cycle progression and cellular growth and proliferation in all three cancer cell lines. Canonical pathway analysis showed the involvement of the NRF2-mediated oxidative stress response, glucocorticoid, p53, RXR-VDR, G1/S checkpoint regulation, ERK, SAPK/JNK and JAS/Stat signaling. Analysis of 234 kinases and phosphatases using a kinase inhibition assay demonstrated a strong inhibitory effect for MAPK14 (104±2%), AMPK A2/B1/G1 (89%) and FGR (83±2%). AURKA was inhibited at 77±1%. MiaPaCa-2 tumor xenograft studies showed a 49.5±14.8% inhibitory effect in mice treated with 100 μg/kg MT477 compared to untreated mice (p=0.0021). Conclusion: MT477 induces molecular mechanisms related to cell death, survival, and inhibition of cellular growth in vitro and in vivo.",

keywords = "AURKA, MT477, NRF2, Tumor growth",

author = "Piotr Jasinski and Pawel Zwolak and Kaoru Terai and Vogel, {Rachel Isaksson} and Daniel Borja-Cacho and Dudek, {Arkadiusz Z.}",

year = "2011",

month = apr,

day = "1",

language = "English (US)",

volume = "31",

pages = "1181--1187",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "4",

}

TY - JOUR

T1 - MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling

AU - Jasinski, Piotr

AU - Zwolak, Pawel

AU - Terai, Kaoru

AU - Vogel, Rachel Isaksson

AU - Borja-Cacho, Daniel

AU - Dudek, Arkadiusz Z.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: The novel compound thiopyrano [2,3-c]quinoline (MT477) has been shown to exhibit antitumor activity in both in vitro and in vivo studies. The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. Materials and Methods/Results: Molecular function analysis revealed changes in genes involved in cell death, cell-cycle progression and cellular growth and proliferation in all three cancer cell lines. Canonical pathway analysis showed the involvement of the NRF2-mediated oxidative stress response, glucocorticoid, p53, RXR-VDR, G1/S checkpoint regulation, ERK, SAPK/JNK and JAS/Stat signaling. Analysis of 234 kinases and phosphatases using a kinase inhibition assay demonstrated a strong inhibitory effect for MAPK14 (104±2%), AMPK A2/B1/G1 (89%) and FGR (83±2%). AURKA was inhibited at 77±1%. MiaPaCa-2 tumor xenograft studies showed a 49.5±14.8% inhibitory effect in mice treated with 100 μg/kg MT477 compared to untreated mice (p=0.0021). Conclusion: MT477 induces molecular mechanisms related to cell death, survival, and inhibition of cellular growth in vitro and in vivo.

AB - Background: The novel compound thiopyrano [2,3-c]quinoline (MT477) has been shown to exhibit antitumor activity in both in vitro and in vivo studies. The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. Materials and Methods/Results: Molecular function analysis revealed changes in genes involved in cell death, cell-cycle progression and cellular growth and proliferation in all three cancer cell lines. Canonical pathway analysis showed the involvement of the NRF2-mediated oxidative stress response, glucocorticoid, p53, RXR-VDR, G1/S checkpoint regulation, ERK, SAPK/JNK and JAS/Stat signaling. Analysis of 234 kinases and phosphatases using a kinase inhibition assay demonstrated a strong inhibitory effect for MAPK14 (104±2%), AMPK A2/B1/G1 (89%) and FGR (83±2%). AURKA was inhibited at 77±1%. MiaPaCa-2 tumor xenograft studies showed a 49.5±14.8% inhibitory effect in mice treated with 100 μg/kg MT477 compared to untreated mice (p=0.0021). Conclusion: MT477 induces molecular mechanisms related to cell death, survival, and inhibition of cellular growth in vitro and in vivo.

KW - AURKA

KW - MT477

KW - NRF2

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=79956067733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956067733&partnerID=8YFLogxK

M3 - Article

C2 - 21508363

AN - SCOPUS:79956067733

SN - 0250-7005

VL - 31

SP - 1181

EP - 1187

JO - Anticancer Research

JF - Anticancer Research

IS - 4

ER -

MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signaling

Abstract

Keywords

UN SDGs

OpenUrl availability

Other files and links

Fingerprint

Cite this